25 results about "Antidote" patented technology

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an inhibitor JSH-23 in preparation of a medicine for preventing and / or treating ovarian toxicity caused by environmental toxin combined exposure. Aiming at the condition that MC-LR and NaNON combined exposure can activate NF-kappa B to induce KK-1 cell nitrification stress and cause mouse ovarian dysfunction, JSH-23 is selected as an intervention agent, and it is found that after KK-1 cells are pretreated by JSH-23, NF-kappa B nuclear translocation induced by the KK-1 cells due to MC-LR and NaNON combined exposure is remarkably inhibited, iNOS protein rising induced by toxin combined exposure is remarkably reduced, and NF-kappa B nuclear translocation induced by the KK-1 cells due to NF-kappa B combined exposure is remarkably inhibited. The increase of the levels of ONOO and 3-NT of nitration stress markers is effectively relieved, which indicates that JSH-23 can participate in the nitration stress of KK-1 cells caused by combined exposure of MC-LR and NaNO2 by inhibiting NF-kappa B activation, and a foundation is laid for screening antidotes after exposure of environmental toxins.

The present application relates to a kind of macromolecular heavy metal complexing agent containing 8-hydroxyquinoline and amido phosphate structure and its preparation method, the present application also relates to a kind of heavy metal antidote, and the use of the macromolecular heavy metal complexing agent of the present application in preparing drug for treating heavy metal poisoning.The macromolecular complexing agent of the present application has excellent binding capacity with cadmium, lead, mercury and other heavy metal ions, and is high in safety, has excellent and long-acting heavy metal protection effect.The preparation method of the present application can mass, simply and efficiently prepare the macromolecular complexing agent of the present application, and preparation process is simple, high in yield, raw material is cheap and easy to obtain, reaction condition is mild.

In alternative embodiments, provided are polyheterocyclic uncharged bisoxime antidotes, including polyheterocyclic uncharged bisoximes, and methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein. In alternative embodiments, provided are methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain; or, treating, ameliorating or protecting (preventing) an organophosphate toxicity or poisoning or toxic exposure, or for treating, ameliorating or protecting (preventing) organophosphate inhibition of an acetylcholinesterase (AChE) comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein.

The invention relates to a nucleic acid aptamer DNA sequence as shown in SEQ ID NO.1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient. The invention also discloses application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of antidote drugs used as ricin and / or abrus precatorius toxin.

This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.

Disclosed are aptamers, aptamer antidotes, and their use in the treatment of thrombosis and other thrombotic conditions.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

The invention discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The invention studies the efficacy of the compound SCH23390 in the treatment of lead poisoning, reveals the treatment effect of the compound SCH23390 on lead poisoning for the first time, breaks through the limitation of existing drug targets, directly corrects abnormal neural signals by inhibiting excessive activation of D1 neurons and avoids the side effect of central hyperexcitation, and has no obvious toxic or side effect under the treatment dosage, especially, the compound SCH23390 can be used for treating lead poisoning. The compound SCH23390 can obviously relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and shows the nerve protection characteristic superior to that of a traditional chelating agent. The limitation that the traditional lead poisoning treatment field depends on a single chelating antidote is broken through, and a brand new direction is provided for developing multi-target and multi-mechanism anti-lead-toxicity drugs.

The invention discloses preparation and application of a skeleton type vomitoxin antidote, and relates to the technical field of feed processing, and the skeleton type vomitoxin antidote is characterized in that the antidote is prepared from 60-70% of Na2S2O5 and 30-40% of a composite carrier through a hot melt extrusion instrument under the conditions that the sleeve outlet temperature is 60-80 DEG C and the screw rotating speed is 30-50 r / min. When the antidote is used for removing vomitoxin in mildewed corn, and the adding level of the effective component skeleton type SMBS is 0.1%, the using effect of the skeleton type vomitoxin antidote is optimal; when the antidote is used for removing DON (deoxynivalenol) in corn alcohol lees polluted by mycotoxin and the addition level of the effective component skeleton-type SMBS is 0.4%, the use effect of the skeleton-type vomitoxin antidote is optimal. A theoretical basis is provided for further development of the corn and the corn alcohol lees in the field of feed processing.

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic aptamers. In particular, the present disclosure provides nucleic acids molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding nucleic acid antidotes, for the modulation of blood coagulation in the context of disease and surgical intervention.

The present application belongs to the technical field of feed additives, and specifically provides a compound preparation for relieving selenium poisoning, which comprises taurine, vitamin E, glutathione, allicin and carotene. The compound preparation provided by the present application utilizes the synergistic effect among taurine, vitamin E, glutathione, allicin and carotene, replaces the commonly used intravenous injection of sodium thiosulfate antidote, slows down the absorption speed of selenium, relieves the oxidation of selenium to the lipid on the surface of liver cell membrane, and removes the by-products such as free radicals after selenium metabolism. By adopting sodium selenite to simulate the environment under acute high-concentration selenium exposure, it is proved that the compound preparation has certain relieving effect on the growth inhibition and liver damage caused by acute selenium poisoning.

The invention relates to a DNA (deoxyribonucleic acid) aptamer which is shown as a formula I and can be specifically combined with abrus precatorius toxin and exert inhibitory activity and application of the DNA aptamer in prevention or treatment of abrus precatorius toxin poisoning. The nucleic acid aptamer can be combined with the abrus precatorius toxin in a high-affinity and high-specificity mode, and the toxicity of the abrus precatorius toxin is effectively resisted. The invention also designs a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient, and an application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of an abrus precatorius toxin antidote drug. In addition, the nucleic acid aptamer can also be used for resisting the abrus precatorius toxin in vitro or used as a detection tool for detecting the abrus precatorius toxin in environmental and biological samples. The invention provides a new solution for first aid, treatment and detection of the abrus precatorius toxin.

The present invention relates to a detoxifying peptide, characterized in that its sequence comprises the following general amino acid sequence: N-(Val-Gly-X1-X2-Pro-Gly)n-OH, in which: N and OH correspond respectively to the N-terminal and C-terminal end of the peptide; X1 and X2 are chosen from valine (Val), glycine (Gly), threonine (Thr), asparagine (Asn), glutamine (Gln), alanine (Ala), leucine (Leu) and isoleucine (Ile); n is an integer between 1 and 3; for use in the treatment and / or prevention of a disorder associated with glycation and / or glycoxidation of proteins and / or lipids.

The invention provides application of beta-glucuronidase in preparation of an antidote for preventing or / and treating zearalenone poisoning and the antidote for preventing or / and treating zearalenone poisoning, and belongs to the field of feed additives. The invention provides a method for reducing the overall exposure level of ZEN by inhibiting the activity of intestinal bacteria beta-glucuronidase from the perspective of in-vivo exposure control of animals for the first time, and the method is clear in technical path and high in operability. The reduction of the in-vivo exposure level of the ZEN is objectively reflected through the change of in-vivo toxicokinetic parameters (AUC, Cmax and / or MRT), and the technical effect can be quantified and verified. The beta-glucuronidase inhibitor adopted by the invention is wide in source, is especially suitable for the field of feed additives, and has a good application prospect.

The invention provides a nano antibody for resisting a C-type botulinum toxin receptor binding domain and application of the nano antibody. The C-type botulinum toxin receptor binding domain is used as an antibody to immunize alpaca, RNA is extracted from mononuclear cells of the alpaca, and the nano antibody resisting the C-type botulinum toxin receptor binding domain is screened from the mononuclear cells by using a phage display library technology. The nano antibody provided by the invention can be specifically bound with a C-type botulinum toxin receptor binding domain, has high affinity, can effectively inhibit specific binding of C-type botulinum toxin and a target cell membrane, and can neutralize the C-type botulinum toxin to play a protective role. The nano antibody provided by the invention is expected to be applied to preparation of C-type botulinum toxin poisoning antidotes. Meanwhile, the nano antibody provided by the invention can be applied to qualitative and quantitative analysis and detection of C-type botulinum toxin as a capture antibody and a detection antibody.

The invention discloses a protection application of nicotinamide mononucleotide in APAP liver injury, and the nicotinamide mononucleotide is applied to preparation of a medicine for protecting or treating acetaminophen-induced acute liver injury. The nicotinamide mononucleotide reduces oxidative stress and liver cell apoptosis caused by acetaminophen by activating a nuclear factor erythrocyte 2 related factor 2 signal channel and inhibiting phosphorylation of c-Jun amino terminal kinase. Through dual mechanisms of activating an Nrf2 antioxidant pathway and inhibiting JNK phosphorylation, oxidative stress and cell apoptosis are relieved from the source, and the defect that an existing antidote NAC is narrow in treatment window is effectively overcome; the NMN is used as a direct precursor of NAD < + >, has good stability and high bioavailability, shows the effects of remarkably increasing the survival rate and improving liver functions and tissue pathological damage in experiments, and provides a brand-new multi-target treatment strategy for APAP poisoning.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when detected. The system employs a progressive challenge-response system to detect unresponsiveness, deliver physical stimuli, administer one or more doses of an antidote, and transmit notifications, thereby improving survival rates in overdose situations. The system and methods include a wearable device that acquires physiological information from an opioid user during an opioid use session, analyzes the information to detect respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present invention relates to supramolecular agents presenting on demand reversibility of activity and related methods. The invention in particular relates to supramolecular agents with anticoagulant activity which can be reversed with the use of an antidote agent.

The invention discloses an application of cajanin, cordyceps polysaccharide or calycosin or a combination of the cajanin, the cordyceps polysaccharide and the calycosin in preparation of drugs for relieving vomitoxin toxicity. According to the application, the cajanin, the cordyceps polysaccharide and the calycosin are independently or jointly used as a feed additive, a medicine for relieving the toxic effect of the vomitoxin or an antidote, and cell inflammation induced by the vomitoxin and damage to the liver, the intestinal tract and the kidney are repaired through the independent or combined effect; the toxicity of vomitoxin to animals can be effectively relieved under the condition of safe dosage, so that the health condition of the animals is improved.

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic activity. In particular, the present disclosure provides nucleic acid molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding antidote nucleic acid molecules capable of modulating anticoagulant activity.

Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are methods of reversing the anti-coagulation effects of the composition by administering an antidote.

The invention belongs to the technical field of traditional Chinese medicine modern preparations, and particularly discloses a centipede toxin-vanquishing decoction nano-micelle transdermal preparation for treating psoriasis and a preparation method thereof.The preparation is prepared from, by weight, 5-15 parts of centipede toxin-vanquishing decoction effective ingredient extract, 20-40 parts of nano-micelle carrier material, 2-8 parts of transdermal absorption enhancer and 37-73 parts of pharmaceutic adjuvants; the centipede toxin-vanquishing drink comprises 3g of centipede, 30g of lithospermum, 30g of rhizoma smilacis glabrae, 30g of ramulus euonymi, 20g of zaocys dhumnade and 10g of liquorice. According to the nano-micelle transdermal preparation for treating psoriasis by adopting the centipede toxin-vanquishing drink and the preparation method of the nano-micelle transdermal preparation, the preparation is based on a classical centipede toxin-vanquishing drink prescription and is combined with a nano-micelle technology, so that the transdermal permeation efficiency of the medicine and the targeting property of a diseased region are improved, the treatment effect is enhanced, the adverse reaction is reduced, meanwhile, the preparation process is stable and controllable, and the cost is low. The method is suitable for industrial production.

Provided herein are methods of treating or preventing venom induced injury, including local tissue damage and / or skin irritation using composition comprising an effective amount of heparin and / or heparinoid. Also provided are uses of said composition in the manufacture of a medicament for treating or preventing the same and said composition for use in treating or preventing the same.

The invention relates to a preparation method of an antidote zeolite imidazate skeleton for central nervous agent poisoning, which comprises the following steps: S100, weighing 2.6 mg of Mal-PEG2000-COOH, dissolving in 5ml of PBS (Phosphate Buffer Solution) with the pH value of 7.4, and carrying out ultrasonic full dissolution to form a first reaction solution; s200, 2 mg of RVG15 is weighed and dissolved in 5 ml of a PBS solution, the PH value of the PBS solution is 7.4, and a second reaction solution is formed after sufficient ultrasonic dissolution; s300, adding the first reaction solution in the step S100 and the second reaction solution in the step S200 into a reaction bottle, reacting for 20-28 hours in a dark place under the condition of nitrogen protection, dialyzing through a 3000Da dialysis bag, removing unreacted substances, and freeze-drying the obtained product for 20-28 hours to prepare RVG15-PEG2000-COOH; s400, weighing HI-6, dissolving HI-6 in a blank ZIF-8 suspension, uniformly stirring to form drug-loaded ZIF-8, centrifuging the drug-loaded ZIF-8 to remove free drugs, and alternately washing the drug-loaded ZIF-8 with methanol and water to prepare HI-6 ZIF-8; and S500, adding the RVG-PEG2000-COOH prepared in the step S300 into the HI-6 (at) ZIF-8 prepared in the step S400, so as to prepare the HI-6 loaded brain targeting ZIF-8.